Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;21(11):e70135.
doi: 10.1111/iwj.70135.

Local wound care management for pyoderma gangrenosum

Adeeb Haroon  1 , Jordan Gillespie  1 , Jaclyn Roland-McGowan  1 , Riyad N H Seervai  1 , Lisa J Gould  2 , Valentina Dini  3 , Alex G Ortega-Loayza  1
Affiliations

Local wound care management for pyoderma gangrenosum

Adeeb Haroon et al. Int Wound J. 2024 Nov.

Abstract

Pyoderma gangrenosum (PG) is a rare, painful neutrophilic dermatosis characterized by rapidly progressing skin ulcers. Despite the importance of local wound care in managing PG, there is no consensus or evidence-based guidelines. This systematic review aimed to investigate local wound care strategies for PG. A comprehensive search of Embase, MEDLINE, and the Cochrane Library yielded 1213 references, from which 269 studies were included, covering 351 patients. The most reported treatment methods included sharp debridement (11%), topical corticosteroids (27%) and non-adherent dressings (12%). However, no clear correlation between these treatments and healing outcomes was found likely due to confounding factors such as varied wound sizes, superinfection and inconsistent reporting. Additionally, directed wound care regimens have not been able to show statistical significance for healing outcomes. Our study describes the current local wound care landscape and underscores a critical gap in the current literature regarding standardized treatment protocols for PG.

PubMed Disclaimer

Conflict of interest statement

AGO‐L reports consultancy/advisory boards disease‐relevant honoraria from Genentech, Boehringer‐Ingelheim, Bristol Mayer‐Squibb and Janssen. AGO‐L also reports research grants from Lilly, Pfizer and Janssen. AGO‐L is also supported by NIAMS NIH R01AR083110. The remaining authors have no conflicts of interest to disclose.

References

    1. Janowska A, Oranges T, Fissi A, Davini G, Romanelli M, Dini V. PG‐TIME: a practical approach to the clinical management of pyoderma gangrenosum. Dermatol Ther. 2020;33(3):e13412. doi:10.1111/dth.13412 - DOI - PubMed
    1. Strunck JL, Cutler B, Latour E, Seminario‐Vidal L, Ortega‐Loayza AG. Wound care dressings for pyoderma gangrenosum. J Am Acad Dermatol. 2022;86(2):458‐460. doi:10.1016/j.jaad.2021.09.053 - DOI - PubMed
    1. Eisendle K, Thuile T, Deluca J, Pichler M. Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and skin grafting, including xenografts: personal experience and comprehensive review on 161 cases. Adv Wound Care. 2020;9(7):405‐425. doi:10.1089/wound.2020.1160 - DOI - PMC - PubMed
    1. Konschake W, Valesky E, Stege H, Jünger M. Evidence of compression therapy. Hautarzt Z Dermatol Venerol Verwandte Geb. 2017;68(8):625‐631. doi:10.1007/s00105-017-3999-z - DOI - PubMed
    1. Dissemond J, Eder S, Läuchli S, Protz K, Traber J, Stücker M. Compression therapy for inflammatory dermatoses of the legs. Dtsch Med Wochenschr 1946. 2024;149(3):106‐112. doi:10.1055/a-2197-6197 - DOI - PubMed

Substances

LinkOut - more resources